Recent Updates — RLYB

Rallybio Corp declared a special cash distribution of an estimated $13.56 per share, totaling approximately $82.7 million, to stockholders and pre-funded warrant holders as part of its proposed merger with Avenzo Therapeutics. The payment is conditioned on the approval of the merger at the annual meeting scheduled for November 4, 2026, with a record date of November 5, 2026, and an expected distribution payment date of November 13, 2026. Nasdaq has set November 6, 2026, as the ex-dividend date due to the distribution exceeding 25% of the stock price, triggering a due bill period from November 4 through November 6. The company also fixed the record date for its previously announced contingent value rights distribution. Rallybio Corp is a clinical-stage biotechnology company focused on developing treatments for rare diseases.